Q32 Bio develops experimental antibody treatments for alopecia areata and other autoimmune and inflammatory diseases. QTTB reports earnings on Thu, Nov 12, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | Leerink Partners | Initiated | Buy | |
| Sep 28 | Jefferies | Initiated | Buy | |
| Aug 24 | Morgan Stanley | Initiated | Buy | |
| Jul 28 | HC Wainwright & Co. | Maintained | Buy | |
| Jul 13 | Wells Fargo | Upgrade | Buy |
Seasonality
How QTTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in QTTB in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QTTB is in one of them and how their past QTTB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered QTTB in an article yet. Here's the latest on the wider market.
About Q32 Bio
Q32 Bio is a biotechnology company in Waltham, Massachusetts, that develops experimental biologic medicines for patients with alopecia areata, a condition that causes hair loss, and other autoimmune and inflammatory diseases. Its lead candidate, bempikibart, is an antibody designed to block two immune signals and is being tested in clinical trials. The company also holds a tissue-targeted complement inhibitor platform, which it is evaluating for strategic options.
- Headquarters
- Waltham, MA